Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

For example, according to the FTC’s lawsuit, in 1999, the average list price of a brand-name insulin, Humalog, was only $21.

This March 1, 2023, photo shows a vial of Eli Lilly's Humalog insulin in New York. (AP Photo/Pablo Salinas) LOS ANGELES (CN) — A Superior Court judge, on Tuesday, told lawyers for the state of ...

For example, according to the FTC’s lawsuit, in 1999, the average list price of a brand-name insulin, Humalog, was only $21. Less than 20 years later, in 2017, it increased to more than $274 ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by ...

According to research, one vial of Lilly's Humalog (insulin lispro) cost $21 in 1999, but had increased to $332 in 2019, representing a price increase of 1480%. The PBMs meanwhile stand accused of ...

Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business ...

28 days Prescribing information Insulin lispro (rDNA origin) vial Humalog vial (Lilly) 28 days Prescribing information NPH, human insulin isophane suspension (rDNA origin) Novolin N vial (Novo ...

The FTC filed a lawsuit in September, accusing the three major PBMs of anticompetitive rebating practices related to insulin.

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) shot up 0% on Tuesday following a dividend announcement from the company. The stock traded as high as $814.00 and last traded at $803.94.

We are aware of reports regarding supply issues of insulin in the UK. Here’s the latest information on how your treatment may be impacted.